Liguori Academy and CMI/Compas Partner to Build Library for Students PHILADELPHIA – November 18, 2020 – Liguori Academy, a nonprofit private high school committed to serving the community, has launched […]
BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period
U.S. and European regulators could approve Pfizer and BioNTech’s experimental Covid-19 vaccine as early as mid-December, the German firm’s chief executive said, following the release of positive trial results.
Abbott became the first anchor sponsor of the American Diabetes Association’s Health Equity Now platform to address health disparities for people with diabetes.
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global Covid-19 pandemic.
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, partnered with WorldQuant Predictive (WQP), a market leader in quantitative predictions and data-driven decisions through a cloud-based artificial intelligence (AI) platform, to improve the end result for patients.
Pfizer-BioNTech and Moderna’s Vaccines Lead the Covid-19 Race; How Do They Compare?
"Operation Warp Speed" Initiative, AstraZeneca, BioNTech, Business, Clinical Trials, Cold chain storage, COVID-19 Vaccines, Efficacy Data, FDA, Interim Data, Messenger RNA (mRNA) Vaccines, Moderna, National Institute of Allergy and Infectious Diseases (NIAID), NPR, Oxford University, Pfizer, R&D, U.S. government, United StatesBioSpace takes a look at Moderna at the similarities between the two, and a few differencesPfizer-BioNTech and Moderna Covid-19 vaccines preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, the U.S. and western countries have the promise of two effective and reasonably safe vaccines. There are . Here’s a look.
A Phase III trial of NurOwn (MSC-NTF cells), BrainStorm Cell Therapeutics’ investigational therapy for amyotrophic lateral sclerosis, did not find a statistically significant difference between the product and placebo for improving scores on a revised ALS functional rating scale (ALSFRS-R) that measures the severity of the disease.
FDA delays decision on Bristol Myers cancer therapy due to Covid-19 travel curbs
Acquisitions, Biologics License Application (BLA), Blood Cancers, Bristol Myers Squibb, Business, Coronavirus Restrictions, Facilities/Sites/Manufacturing, FDA, Investors, R&D, Relapsed Or Refractory (R/R) Large B-Cell Lymphoma (LBCL), TexasBristol Myers Squibb said the U.S. health regulator deferred a decision on an experimental blood cancer therapy that the company acquired in the $74 billion buyout of Celgene due to coronavirus-related travel restrictions.
The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for Sanofi’s blood cancer treatment sutimlimab.